VII. FOLLOW-UP

 

 

Follow-up na behandeling van primair mammacarcinoom heeft vier motieven:

1. zorg voor de patiŽnte

2. detectie van recidief ziekteactiviteit

3. detectie van een 2e primaire tumor

4. medisch-technische aspecten die gericht zijn op het in kaart brengen en behandelen van de gevolgen van de behandeling

 

 

 

1. Locoregionaal recidief

 

Zie gelijknamige hoofdstuk.

 

 

 

 

2. Metastasen op afstand

 




 

 

3. Nieuwe primaire tumor in de contralaterale mamma

 


 

 

4. Bijwerkingen van de therapie van primair mammacarcinoom

 

 


 

 


5. Anticonceptie en zwangerschap na behandeling

Ongeveer 15% van alle vrouwen met borstkanker is jonger dan 45 jaar en heeft mogelijk nog een kinderwens. Wanneer een vrouw besluit zwanger te willen worden is het raadzaam recidief mammacarcinoom of een tweede primaire tumor zoveel mogelijk uit te sluiten met behulp van mammografie. Ook wordt geadviseerd dan de behandeling met tamoxifen te staken.

Het gebruik van orale anticonceptie wordt afgeraden bij borstkankerpatiŽnten. Dit advies is gebaseerd op indirecte bewijsvoering: de rol van oestrogenen in het ontstaan van borstkanker en de bewezen effectiviteit van anti- oestrogene therapie bij borstkanker.

 



 

 

 

6. Hormonale suppletietherapie bij vrouwen met borstkanker

 




 

Referenties

1.†††† Roselli Del Turco M, Palli D, Cariddi A, Ciatto S, Pacini P. Distante V. Intensive diagnostic follow-up after treatment of primary breast cancer: a randomized trial. JAMA 1994; 271: 1593-7.

2.†††† GIVIO (Interdisciplinary Group for Cancer Care Evaluation) Investigators. Impact of follow-up and testing on survival and health-related quality of life in breast cancer patients: a multicenter randomized controlled trial. JAMA 1994; 271: 1587-92.

3.†††† Mellink WAM, Holland R, Hendriks JHCL, Peeters PHM, Rutgers EJT, van Daal WAJ. The contribution of routine follow-up mammography to an early detection of asynchronous contralateral breast cancer. Cancer 1991; 67 : 1844-8.

4.†††† Robinson E, Rennert G, Rennert HS, Neugut AI. Survival of first and second primary breast cancer. Cancer 1993;71:172-6.

5.†††† Roubidoux MA, Helvie MA, Lai NE, Paramagul C. Bilateral breast cancer: early detection with mammography. Radiology 1995; 196: 427-31.

6.†††† Kaas R, Hart AAM, Besnard APE, Peterse JL, Rutgers EJT. Impact of mammographic interval on stage and survival after the diagnosis of contralateral breast cancer. Br J Surg 2001; 88: 123-7.

7.†††† Early Breast Cancer Trialistsí Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials, Lancet 1998; 352: 930-42.

8.†††† Shapiro CL, Hardenbergh PH, Gelman R, Blanks D, Hauptman P, Recht A, et al. Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients. J Clin Oncol 1998; 16: 3493-501.

9.†††† Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M. D. Anderson Hospital and Tumor Institute. In: Lippman ME, ed. National Institutes of health Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. NCI monographs. No.1 Washington D.C.: Government Printing Office, 1986:105-9. (NIH publication no. 86-2860)

10.Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. Ann Intern Med 1996; 125: 47-58.

11.Valagussa P, Moliterni A, Zambetti M, Bonadonna G. Long-term sequelae from adjuvant chemotherapy. Recent Results Cancer Res 1993; 127: 247-255.

12.Gennari A, Salvadori R, Donati S, Bengala C, Orlandini C, Danesi R, et al. Cardiotoxicity of epirubicin/paclitaxel-containing regimens: role of cardiac risk factors. J Clin Oncol 1999; 17: 3596-602.

13.Early Breast Cancer Trialistsí Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-67.

14.Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following

††††† ††Tamoxifen. Lancet 2000; 356: 881-7.

15.Bernstein L, Deapen D, Cerhan JR, Schwartz SM, Liff J, McGann-Maloney E, et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 1999; 91: 1654-62.

16.Love CD, Muir BB, Scrimgeour JB, Leonard RC, Dillon P, Dixon JM. Investigation of endometrial abnormalities in asymptomatic women treated with tamoxifen and an evaluation of the role of endometrial screening. J Clin Oncol 1999; 17: 2050-4.

17.Gerber B, Krause A, MŁller H, Reimer T, Kulz T, Makovitzky J, et al. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol 2000; 18: 3464-70.

18.Sankila R, Heinavaara S, Hakulinen T. Survival of breast cancer patients after subsequent term pregnancy. Am J Obstet Gynecol 1994; 170: 818-23.

19.Schoultz E von, Johansson H, Wilking N, Rutqvist LE. Influence of prior and subsequent pregnancy on breast cancer prognosis. J Clin Oncol 1995; 13:430-4.

20.Kroman N, Jensen MB, Melbye M, Wohlfahrt J, Mouridsen HT. Should women be advised against pregnancy after breast-cancer treatment? Lancet 1997; 350: 319-22.

21.O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93: 754-62.